{
    "clinical_study": {
        "@rank": "31666", 
        "arm_group": [
            {
                "arm_group_label": "Immune Globulin Intravenous", 
                "arm_group_type": "Experimental", 
                "description": "IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg."
            }, 
            {
                "arm_group_label": "Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "An equivalent volume (weight-based)of normal saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether intravenous immune globulin is safe and\n      effective in the acute treatment of pain crises in sickle cell disease.\n\n      Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development\n      (OOPD)"
        }, 
        "brief_title": "Intravenous Gammaglobulin for Sickle Cell Pain Crises", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Sickle Cell Disease", 
            "Pain"
        ], 
        "condition_browse": {
            "mesh_term": "Anemia, Sickle Cell"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented diagnosis of sickle cell disease (SS or S-\u03b2 thalassemia genotype)\n\n          -  Age 12-65 years\n\n          -  Uncomplicated acute pain episode requiring hospital admission and parenteral\n             narcotics\n\n        Exclusion Criteria:\n\n          -  Increased stroke risk as assessed by transcranial Doppler or magnetic resonance\n             imaging (all subjects undergo testing)\n\n          -  Concomitant acute process, including fever > 38.5\u00b0 C with clinical suspicion of\n             infection\n\n          -  Increased ALT > 2X ULN\n\n          -  Serum creatinine \u22651.3 mg/dL, >300 mg/dL protein in spot urinalysis, or known\n             condition associated with renal dysfunction\n\n          -  Hb > 10 g/dL and Hct > 30%\n\n          -  Known IgA deficiency or known allergy to gamma globulin\n\n          -  Pregnancy or breastfeeding\n\n          -  Vaccination with a live attenuated virus in the preceding 6 weeks\n\n          -  Documented history of illicit (eg. heroin, cocaine) drug abuse or drug-seeking\n             behavior\n\n          -  Current participation in another investigational drug study\n\n          -  Current treatment with chronic transfusion\n\n          -  Prior thromboses or current estrogen use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00644865", 
            "nct_id": "NCT01757418", 
            "org_study_id": "7R01FD003447-03", 
            "secondary_id": "FD-R-003447-01-A1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Immune Globulin Intravenous", 
                "description": "A single dose of intravenous immune globulin or saline placebo administered within 18 hours of hospital presentation. The current maximum dose planned is 800 mg/kg.", 
                "intervention_name": "Immune Globulin Intravenous", 
                "intervention_type": "Drug", 
                "other_name": "GAMUNEX (Talecris Biotherapeutics)"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gamma-Globulins", 
                "Antibodies", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sickle Cell Disease", 
            "Pain", 
            "Immune Globulin"
        ], 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "contact": {
                "email": "dmanwani@montefiore.org", 
                "last_name": "Deepa G Manwani, MD", 
                "phone": "718-741-2342"
            }, 
            "facility": {
                "address": {
                    "city": "Bronx", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10467"
                }, 
                "name": "Montefiore Medical Center"
            }, 
            "investigator": {
                "last_name": "Deepa G Manwani, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain", 
        "overall_contact": {
            "email": "dmanwani@montefiore.org", 
            "last_name": "Deepa G Manwani, M.D", 
            "phone": "718-741-2342"
        }, 
        "overall_contact_backup": {
            "email": "kireland@montefiore.org", 
            "last_name": "Karen Ireland", 
            "phone": "718-741-2401"
        }, 
        "overall_official": {
            "affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "last_name": "Deepa G Manwani, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "End of crisis defined as either 1) Pain score consistently \u2264 5 (on the visual analog or Wong-Baker FACES scale) AND off of IV opioids or 2) Hospital discharge", 
            "measure": "Duration of pain crisis", 
            "safety_issue": "No", 
            "time_frame": "Number of days from study drug infusion to end of crisis, average 4 days and maximum 30days"
        }, 
        "reference": [
            {
                "PMID": "17932253", 
                "citation": "Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008 Jan 15;111(2):915-23. Epub 2007 Oct 11."
            }, 
            {
                "PMID": "14630831", 
                "citation": "Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004 Mar 15;103(6):2397-400. Epub 2003 Nov 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757418"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "investigator_full_name": "Deepa Manwani", 
            "investigator_title": "Director, Sickle Cell Disease Program, Children's Hospital at Montefiore", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "End of crisis defined as either: 1)Pain score consistently \u2264 5 (on the visual analog or Wong-Baker FACES scale AND off of IV opioids or 2) Hospital discharge", 
            "measure": "Total opioid use in equivalent of mg of IV morphine", 
            "safety_issue": "No", 
            "time_frame": "From study drug infusion to end of crisis, average 4 days and maximum 30days"
        }, 
        "source": "Albert Einstein College of Medicine of Yeshiva University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Albert Einstein College of Medicine of Yeshiva University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}